New Information about
GAGs for more than joints
References:
1. Lassus, A. et al.: Imdeen for the treatment of degenerated skin in females. Joumal of Int'l Research 19(2): 147-52. 2. Cooper ML, Hansbrough JF: Use of a composite skin graft composed of fibroblasts and a collagen-GAG matrix to cover full-thickness wounds. Surgery 1991 ;109(2):198-2-7. 3. Breborowitz A, et al.: Glycosaminoglycan chondroitin sulfate prevent loss of ultra filtration during peritoneal dialysis in rats. Nephron 1994;67(3):346-350. Available from Neogen, 628 Winchester Rd., Lexingtron, KY 40505; (800) 477-8201.
The use of glycosaminoglycans (GAGs) for joint protection and therapy has been much publicized, and now Neogen Corporation is distributing ChondroprotecTM, from the Hymed Group, for use in the management of pressure ulcers, venous stasis ulcers, trauma injuries, partial and full thickness wounds, donor sites and bums. ChondroprotectT M is a sterile 10 ml solution containing 1,000 mg of polysulfated glycosaminoglycan. Sodium hydroxide and/or hydrochloric acid is added when necessary to adjust pH to 6.5-6.7. Recent research has shown that GAGs have become beneficial in the management of chronic and acute wounds. "ChondroprotecTM creates optimal moist wound healing environment, protects new granulation tissue, conforms to any wound site, promotes natural autolysis by rehydrating and softening necrotic tissue and eschar, encourages autolytic debridement, and is easy to apply and redress," according to Anita M. Petito of the Hymed Group. The wound is first irrigated with normal saline and the ChondroprotecTM is applied liberally to the wound surface. It is then covered with extra gauze or an ABD pad. Then after the heavy drainage has subsided (24-96 hours), the wound is covered with a Telfa pad. Wounds that are contaminated and/or infected should be debrided prior to using the product.
Topical DMSO for joint inflammation
Am J Vet Res 1998;159:1149-1152.
Topically applied dimethylsulfoxide (DMSO) penetrated into synovial fluid in sufficient quantities to be detected and to decrease joint inflammation, in a recent study. The six horses studied had Lipopolysaccharide (LPS)-induced synovitis in the midcarpal joint. There were six control horses. All horses were evaluated by serial lameness examinations and synovial fluid analyses (total and differential WBC count and total protein concentration) at 12-hour intervals for 60 hours after LPS injection. Plasma and synovial fluid were obtained at baseline and 36 hours to document presence of DMSO.
Stress fractures in racehorses According to a study by KK Haussler and SM Stover, 36 Thoroughbred racehorses that died at California racetracks between October 1993 and July 1994 were evaluated for stress fractures in the caudal portion of the thoracic and lumbosacral regions of the spine and the pelvis. The lumbosacral spine and pelvis were collected, debrided of soft tissues and examined visually for the presence of an incomplete fracture line and focal periosteal proliferation, characteristic of a stress fracture. Sixty-one per cent of specimens had evidence of stress fracture in the caudal portion of the thoracic and lumbosacral regions of the spine and the pelvis. Vertebral lamina stress fractures were found in 50% of specimens and were positively associated with the severity of dorsal spinous process impingement and overall severity of articular process
720
JOURNAL OF EQUINE VETERINARY SCIENCE